Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

River blindness vaccine set for cattle trials
The vaccine is being developed by biotechnology company Vaxine Pty.

Vaccine uses unique sugar-based adjuvant

Scientists in Australia are developing a vaccine that could prevent millions of cases of river blindness.

According to The Lead South Australia, the vaccine is being developed by biotechnology company Vaxine Pty and is set for trials in 2017.

Vaxine scientific director Nikolai Petrovsky explained that the vaccine uses a two-pronged approach to effectively prevent the disease.


“First we’re looking to vaccinate the cattle, which are a breeding ground for the parasite,” he said. 
“Then, the other side of this is to immunise the children so if they come in contact with the parasite it blocks the infection.


“Our technology is a bit like melding a turbocharger to the engine and in this case makes the vaccine dramatically more powerful.”

According to the World Health Organisation, river blindness affects some 17 million people globally. Ninety per cent of these cases occur in west and central Africa.


Caused by the parasitic worm Onchocerca volvulus, river blindness is spread to humans and cattle by blackflies that breed in rivers. Symptoms of the disease include severe itching, disfigurative skin conditions and visual impairment - including permanent blindness.

Professor Petrovsky said the new vaccine uses a unique sugar-based adjuvant, which is safer than existing methods.

“We offer a new alternative that is not only potentially safer because it is a sugar instead of a metal/salt with high toxicity,” he told The Lead. 

“Our adjuvant also works for a lot of vaccines that wouldn’t work with aluminium. The ones that tried to create an onchocerciasis vaccine didn’t take but ours actually works.”

The vaccine was developed in association with Thomas Jefferson University and the New York Blood Centre in the United States.

The team have received a grant from the US government and hope to begin tests for the cattle trial in the coming weeks.

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'